stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) Net income
Maravai LifeSciences Holdings, Inc.'s net income for fiscal 2025 was −$230.8M, compared with −$259.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$115.0M. Over the past ten years it has ranged from −$259.6M (fiscal 2024) to $490.7M (fiscal 2022); the current reading is higher than 22% of that period. Maravai LifeSciences Holdings, Inc. ranks 447th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$230.8M | — |
| FY2024 | −$259.6M | — |
| FY2023 | −$138.4M | — |
| FY2022 | $490.7M | 4.56% |
| FY2021 | $469.3M | 495.37% |
| FY2020 | $78.8M | — |
| FY2019 | −$5.2M | — |
| FY2018 | −$16.9M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$24.0M | — |
| Jun 2026 | −$21.6M | — |
| Mar 2026 | −$6.4M | — |
| Dec 2025 | −$63.0M | — |
| 25 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $178.6M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $16.3M |
| TRVI Trevi Therapeutics, Inc. compare | −$51.1M |
| SRPT Sarepta Therapeutics, Inc. compare | −$114.6M |
| MRVI Maravai LifeSciences Holdings, Inc. | −$115.0M |
| MESO Mesoblast Limited compare | −$128.6M |
| MAZE Maze Therapeutics, Inc. compare | −$133.6M |
| VIR Vir Biotechnology, Inc. compare | −$184.8M |
| REPL Replimune Group, Inc. compare | −$271.0M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item